A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C

Hepatology

Volumn 29, Issue 4, 1999, Pages 1280-1287

  Zeuzem, Stefan ^a   Hopf, Uwe ^b   Carreno, Vicente ^c   Diago, Moisés ^d   Shiffman, Mitchell ^e   Grüne, Stefan ^f   Dudley, Francis J ^g   Rakhit, Ashok ^h   Rittweger, Karen ^h   Yap, Sing Hiem ⁱ   Koff, Raymond S ^j   Thomas, Howard C ^k  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^e VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^g ALFRED HOSPITAL   (Australia)

^h HOFFMANN LA ROCHE INC   (United States)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j METROWEST MEDICAL CENTER   (United States)

^k Mary's Hospital   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CYTOKINE ANTIBODY; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 12; VIRUS RNA;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY RESPONSE; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FEMALE; HEPATITIS C; HUMAN; IMMUNOPOTENTIATION; INTERFERON PRODUCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS LOAD;

EID: 0032898744     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510290429     Document Type: Article

References (9)

1. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, et al. for the Sentinel Counties Chronic Non-A, Non-B Hepatitis Study Team. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-1905.
2. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466.
3. van der Poel CL, Cuypers HT, Reesink HW. Hepatitis C virus six years on. Lancet 1994;344:1475-1479.
4. Lindsay KL. Therapy of hepatitis C: overview. HEPATOLOGY 1997; 26(Suppl 1):71S-77S.
5. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127: 875-881.
6. Rumi M, del Ninno E, Parravicini ML, Romeo R, Soffredini R, Donato MF, Wilber J, et al. A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C. HEPATOLOGY 1996;24:1366-1370.
7. Zeuzem S, Lee J-H, Franke A, Rüster B, Prümmer O, Herrmann G, Roth WK. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. HEPATOLOGY 1998;27:1149-1156.
8. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. for the International Hepatitis Interventional Therapy Group (IHIT). Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432.
9. Reichard O, Norkrans G, Frydén A, Braconier J-H, Sönnerborg A, Weiland O for the Swedish Study Group. Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83-87.